Effect of Heparin and/or Antithrombin III on the Generation of Endotoxin-Induced Plasminogen Activator Inhibitor

Summary It has been experimentally shown that endotoxin induces a significant increase in the blood levels of a plasminogen activator inhibitor (PAI). We evaluated the effect of different doses of heparin (5 to 20IU kg−1 h−1), antithrombin III (10 to 40 U kg−1 h−1 and 240 U/kg as bolus) and of a combination of the two on: 1) the elevation of PAI activity, 2) fibrin deposition in kidneys and 3) mortality in rabbits infused with E. coli lipopoly-saccharide. Our results show that heparin plus AT III is able to significantly reduce the generation of endotoxin-induced PAI activity in rabbits' circulation. Low dose of heparin and a bolus injection of AT III both cause a decrease in the generation of PAI at 2 but not at 6 hours of endotoxin infusion. Moreover, fibrin deposits in kidneys of animals receiving heparin plus AT III or a bolus injection of AT III were significantly reduced as compared to control rabbits. The association between low levels of PAI and decreased fibrin deposits is strengthened by the significant correlation (p < 0.05) found between these two parameters. Finally, the plasma levels of PAI activity at 2 and 6 hours of endotoxin infusion in surviving animals were lower than those observed in animals that died within 2 hours after the end of treatment. We conclude that heparin plus AT III partially prevents the endotoxin-induced generation of PAI activity which seems to correlate with the reduced presence of fibrin deposits in kidneys and with a reduced mortality.

[1]  B. Schwartz,et al.  Increased release of plasminogen activator inhibitor type 2 accompanies the human mononuclear cell tissue factor response to lipopolysaccharide. , 1988, Blood.

[2]  N. Semeraro,et al.  358 Thrombin infusion in endotoxin-treated rabbits reduces the plasma levels of plasminogen activator inhibitor (PAI): Evidence for a protein C (PC)-mediated mechanism , 1988 .

[3]  J. Paramo,et al.  Preoperative Identification of Patients at High Risk of Deep Venous Thrombosis Despite Prophylaxis in Total Hip Replacement , 1988, Thrombosis and Haemostasis.

[4]  J. Paramo,et al.  Inhibition of one-chain and two-chain forms of human tissue-type plasminogen activator by the fast-acting inhibitor of plasminogen activator in vitro and in vivo. , 1986, The Journal of laboratory and clinical medicine.

[5]  J. Paramo,et al.  Influence of the fast-acting inhibitor of plasminogen activator on in vivo thrombolysis induced by tissue-type plasminogen activator in rabbits. Interference of tissue-derived components. , 1986, The Journal of clinical investigation.

[6]  T. Gelehrter,et al.  Thrombin induction of plasminogen activator-inhibitor in cultured human endothelial cells. , 1986, The Journal of clinical investigation.

[7]  J. Paramo,et al.  Plasminogen Activator Inhibitor (PA-lnhibitor) Activity in the Blood of Patients with Deep Vein Thrombosis , 1985, Thrombosis and Haemostasis.

[8]  J. Paramo,et al.  Postoperative Changes in the Plasmatic Levels of Tissue-Type Plasminogen Activator and Its Fast-Acting Inhibitor - Relationship to Deep Vein Thrombosis and Influence of Prophylaxis , 1985, Thrombosis and Haemostasis.

[9]  F. Werf,et al.  Plasminogen activator inhibitor in the blood of patients with coronary artery disease. , 1985, British medical journal.

[10]  J. Paramo,et al.  Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. , 1985, The Journal of clinical investigation.

[11]  D. Collen,et al.  Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions. , 1984, Thrombosis research.

[12]  B. Mizock Septic Shock: A Metabolic Perspective , 1984 .

[13]  B. Wiman,et al.  Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. , 1983, Thrombosis research.

[14]  N. Semeraro,et al.  Cultured human endothelial cells generate tissue factor in response to endotoxin. , 1983, The Journal of clinical investigation.

[15]  D. Loskutoff,et al.  Interactions between fibrin and the plasminogen activators produced by cultured endothelial cells. , 1983, Blood.

[16]  E. Mullaart,et al.  A Simple, Sensitive Spectrophotometric Assay for Extrinsic (Tissue-Type) Plasminogen Activator Applicable to Measurements in Plasma , 1982, Thrombosis and Haemostasis.

[17]  D. Collen On the Regulation and Control of Fibrinolysis , 1980, Thrombosis and Haemostasis.

[18]  S. Bradley Cellular and molecular mechanisms of action of bacterial endotoxins. , 1979, Annual review of microbiology.

[19]  R. Ulevitch,et al.  The effects of bacterial endotoxins on host mediation systems. A review. , 1978, The American journal of pathology.

[20]  K. Ohlsson,et al.  Release of Granulocyte Elastase in Lethal Canine Endotoxin Shock , 1978, Hoppe-Seyler's Zeitschrift fur physiologische Chemie.

[21]  K. Havemann,et al.  Demonstration of granulocytic proteases in plasma of patients with acute leukemia and septicemia with coagulation defects. , 1977, Blood.

[22]  A. Michael,et al.  Renal Cortical Fibrinolytic Activity in the Rabbit Following One or Two Doses of Endotoxin , 1973, Thrombosis and Haemostasis.

[23]  P. Lalezari,et al.  A Rapid, Simple, Sensitive Method for Measuring Fibrinolytic Split Products in Human Serum∗ , 1969, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.